Amgen Inc. $AMGN Stock Acquired by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. raised its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.6% in the third quarter, Holdings Channel.com reports. The fund owned 85,661 shares of the medical research company’s stock after acquiring an additional 2,141 shares during the quarter. Amgen makes up approximately 0.6% of Sumitomo Mitsui Financial Group Inc.’s portfolio, making the stock its 29th biggest holding. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $36,107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Wellington Altus USA Inc. grew its position in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after buying an additional 55 shares during the period. Nvwm LLC lifted its stake in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares in the last quarter. Security National Bank of Sioux City Iowa IA purchased a new stake in Amgen during the second quarter worth about $36,000. Finally, PFS Partners LLC lifted its holdings in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after buying an additional 42 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. Leerink Partners raised their target price on shares of Amgen from $395.00 to $464.00 and gave the company a “market perform” rating in a report on Thursday, November 5th. Weiss Ratings upgraded shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. TD Cowen upped their price target on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. raised their price target on Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Finally, Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $428.62.

Check Out Our Latest Stock Analysis on AMGN

Amgen Stock Down 0.8%

Shares of AMGN opened at $435.52 on Friday. The company’s fifty day moving average is $430.44 and its two-hundred day moving average is $383.81. The firm has a market cap of $235.58 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 3.22 and a beta of 0.43. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same quarter last year, the firm posted $5.64 earnings per share. Amgen’s revenue for the quarter was up 8.5% compared to the same quarter last year. Analysts forecast that Amgen Inc. will post 23.41 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

Amgen Company Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.